JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH oxidase. In addition, pitavastatin reduces the expression of eNOS mRNA while increasing the NO dependent response stimulated by acetylcholine and the calcium ionophore, A23187. Furthermore, pitavastatin inhibits the up-regulation of conductance calcium-activated potassium channels by lowering cholesterol levels in cells.
Cell lines
Huh-7 and SMMC7721 liver cancer cell lines
Preparation method
The solubility of this compound in DMSO is >34.9mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
Reacting condition
0-20 μM
Applications
In the liver cancer Huh-7 cells and SMMC7721 cells, pitavastatin inhibited cell growth in a dose-dependent way and inhibited colony formation. Pitavastatin significantly arrested the Huh-7 cells at the G1 phase and increased the proportion of sub-G1 phase cells. Pitavastatin induced apoptosis dependent of caspases.
Animal models
Experimental autoimmune myocarditis (EAM) BALB/c mice
Dosage form
5 mg/kg; 3 weeks from day 0 to day 21; orally
Application
In experimental autoimmune myocarditis (EAM) BALB/c mice, pitavastatin reduced the pathophysiological severity of the myocarditis. Pitavastatin inhibited the phosphorylation of STAT3 and STAT4, and suppressed production of Th1 cytokine interferon-γ and Th17 cytokine interleukin-17 from autoreactive CD4+T cells in the heart.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1] You HY1, Zhang WJ1, Xie XM1, et al. Pitavastatin suppressed liver cancer cells in vitro and in vivo. Onco Targets Ther. 2016 Aug 29;9:5383-8.
[2]. Tajiri K1, Shimojo N, Sakai S, et al. Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther. 2013 Oct;27(5):413-24.